NASDAQ:IMMU - Immunomedics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $22.39 -0.15 (-0.67 %) (As of 09/18/2018 04:00 PM ET)Previous Close$22.54Today's Range$22.14 - $23.0052-Week Range$8.68 - $27.33Volume1.07 million shsAverage Volume2.20 million shsMarket Capitalization$4.16 billionP/E Ratio-21.91Dividend YieldN/ABeta1.79 Company ProfileDiscussionAnalyst RatingsChartEarnings HistoryFinancialsInsider TradesHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Immunomedics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders, and other diseases. The company engages in developing antibody-drug conjugate (ADC) products comprising IMMU-132, an ADC that contains SN-38, which is in Phase II trials used for the treatment of patients with metastatic triple-negative breast cancer, and small-cell and non-small-cell lung cancers; IMMU-130, an anti-CEACAN5-SN-38 ADC that is in Phase II trials for the treatment of solid tumors and metastatic colorectal cancer; and IMMU-140 that targets HLA-DR for the potential treatment of liquid cancers. It also develops products for the treatment of cancer and autoimmune diseases, including epratuzumab, anti-CD22 antibody; veltuzumab, anti-CD20 antibody; milatuzumab, anti-CD74 antibody; and IMMU-114, a humanized anti-HLA-DR antibody. The company also provides LeukoScan, a diagnostic imaging product to determine the location and extent of infection/inflammation in bone. In addition, it offers other product candidates for the treatment of solid tumors and hematologic malignancies, as well as other diseases, which are in various stages of clinical and pre-clinical development. The company has a research collaboration with The Bayer Group to study epratuzumab as a thorium-227-labeled antibody; a collaboration agreement with University of Wisconsin Carbone Cancer Center to expand IMMU-132 into prostate cancer; and a collaboration agreement with Yale Cancer Center to evaluate its ADC product as a single agent in two phase II studies in patients with persistent or recurrent endometrial and cervical cancers. Immunomedics, Inc. was founded in 1982 and is headquartered in Morris Plains, New Jersey. Receive IMMU News and Ratings via Email Sign-up to receive the latest news and ratings for IMMU and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Diagnostic substances Sub-IndustryBiotechnology SectorMedical SymbolNASDAQ:IMMU CUSIP45290710 Webwww.immunomedics.com Phone973-605-8200 Debt Debt-to-Equity Ratio0.05 Current Ratio14.83 Quick Ratio14.83 Price-To-Earnings Trailing P/E Ratio-21.91 Forward P/E Ratio-20.54 P/E GrowthN/A Sales & Book Value Annual Sales$2.16 million Price / Sales1,936.63 Cash FlowN/A Price / CashN/A Book Value$2.39 per share Price / Book9.37 Profitability EPS (Most Recent Fiscal Year)($1.03) Net Income$-273,830,000.00 Net Margins-12,701.21% Return on Equity-124.54% Return on Assets-38.70% Miscellaneous Employees185 Outstanding Shares186,830,000Market Cap$4.16 billion Immunomedics (NASDAQ:IMMU) Frequently Asked Questions What is Immunomedics' stock symbol? Immunomedics trades on the NASDAQ under the ticker symbol "IMMU." How were Immunomedics' earnings last quarter? Immunomedics, Inc. (NASDAQ:IMMU) released its quarterly earnings results on Thursday, August, 23rd. The biopharmaceutical company reported ($0.68) earnings per share for the quarter, missing analysts' consensus estimates of ($0.22) by $0.46. The biopharmaceutical company had revenue of $0.40 million for the quarter, compared to analyst estimates of $4.27 million. Immunomedics had a negative return on equity of 124.54% and a negative net margin of 12,701.21%. The company's revenue was down 33.3% compared to the same quarter last year. During the same period last year, the company earned ($0.48) EPS. View Immunomedics' Earnings History. When is Immunomedics' next earnings date? Immunomedics is scheduled to release their next quarterly earnings announcement on Thursday, November, 8th 2018. View Earnings Estimates for Immunomedics. What price target have analysts set for IMMU? 5 analysts have issued twelve-month price objectives for Immunomedics' shares. Their forecasts range from $27.00 to $55.00. On average, they expect Immunomedics' stock price to reach $36.40 in the next year. This suggests a possible upside of 62.6% from the stock's current price. View Analyst Price Targets for Immunomedics. What is the consensus analysts' recommendation for Immunomedics? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Immunomedics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Immunomedics. Who are some of Immunomedics' key competitors? Some companies that are related to Immunomedics include IPSEN S A/S (IPSEY), Neogen (NEOG), Myriad Genetics (MYGN), Quidel (QDEL), Intellia Therapeutics (NTLA), Meridian Bioscience (VIVO), Lantheus (LNTH), Oxford Immunotec Global (OXFD), Quotient (QTNT), Nymox Pharmaceutical (NYMX), Trinity Biotech (TRIB), Celldex Therapeutics (CLDX), Riot Blockchain (RIOT), ImmuCell (ICCC) and Vermillion (VRML). Who are Immunomedics' key executives? Immunomedics' management team includes the folowing people: Mr. Michael R. Garone, CFO, Principal Accounting Officer & VP of Fin. (Age 59)Mr. Michael F. Pehl, Pres, CEO & Director (Age 53)Ms. Phyllis Parker, Director of Admin.Dr. Chau Cheng, Sr. Director of Investor Relations & Corp. Sec.Dr. William A. Wegener, Chief Medical Officer Has Immunomedics been receiving favorable news coverage? Media stories about IMMU stock have trended somewhat positive on Tuesday, according to Accern. The research firm ranks the sentiment of press coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Immunomedics earned a news and rumor sentiment score of 0.18 on Accern's scale. They also assigned media coverage about the biopharmaceutical company an impact score of 46.57 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near future. View Recent Headlines for Immunomedics. Who are Immunomedics' major shareholders? Immunomedics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.71%), FMR LLC (4.55%), Orbimed Advisors LLC (2.95%), Acuta Capital Partners LLC (2.84%), Millennium Management LLC (2.24%) and Janus Henderson Group PLC (1.92%). Company insiders that own Immunomedics stock include Behzad Aghazadeh, Brian A Markison, Cynthia L Goldenberg, David M Goldenberg and Venbio Select Advisor Llc. View Institutional Ownership Trends for Immunomedics. Which major investors are selling Immunomedics stock? IMMU stock was sold by a variety of institutional investors in the last quarter, including Acuta Capital Partners LLC, Orbimed Advisors LLC, DAFNA Capital Management LLC, First Trust Advisors LP, Wells Fargo & Company MN, Alps Advisors Inc., PNC Financial Services Group Inc. and EAM Global Investors LLC. Company insiders that have sold Immunomedics company stock in the last year include Brian A Markison and David M Goldenberg. View Insider Buying and Selling for Immunomedics. Which major investors are buying Immunomedics stock? IMMU stock was bought by a variety of institutional investors in the last quarter, including RA Capital Management LLC, BlackRock Inc., American Century Companies Inc., Voya Investment Management LLC, Janus Henderson Group PLC, Millennium Management LLC, FMR LLC and Menora Mivtachim Holdings LTD.. Company insiders that have bought Immunomedics stock in the last two years include Behzad Aghazadeh and Venbio Select Advisor Llc. View Insider Buying and Selling for Immunomedics. How do I buy shares of Immunomedics? Shares of IMMU can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Immunomedics' stock price today? One share of IMMU stock can currently be purchased for approximately $22.38. How big of a company is Immunomedics? Immunomedics has a market capitalization of $4.16 billion and generates $2.16 million in revenue each year. The biopharmaceutical company earns $-273,830,000.00 in net income (profit) each year or ($1.03) on an earnings per share basis. Immunomedics employs 185 workers across the globe. How can I contact Immunomedics? Immunomedics' mailing address is 300 AMERICAN RD, MORRIS PLAINS NJ, 07950. The biopharmaceutical company can be reached via phone at 973-605-8200 or via email at [email protected] MarketBeat Community Rating for Immunomedics (NASDAQ IMMU)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 262 (Vote Outperform)Underperform Votes: 222 (Vote Underperform)Total Votes: 484MarketBeat's community ratings are surveys of what our community members think about Immunomedics and other stocks. Vote "Outperform" if you believe IMMU will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IMMU will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 9/18/2018 by MarketBeat.com StaffFeatured Article: How Do You Make Money With Penny Stocks?